Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain-Boosting supplement put to the test in new clinical trial

NCT ID NCT07267845

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether taking a daily supplement called Alpha-Glycerophosphocholine (α-GPC) can improve thinking, memory, and physical performance in healthy adults aged 25 to 55. Over 6 weeks, 80 participants will take either α-GPC or a placebo pill, and complete tests of attention, reaction time, and exercise. The goal is to see if α-GPC is safe and effective for enhancing everyday mental and physical function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 55 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Be able to give written informed consent. * Be in good health as determined by the investigator. * Age between 25 and 55 years (inclusive). * Body Mass Index of 18.5-32.0 kg/m2 (inclusive). * Body weight of at least 54 kilograms. * Muscle strengthening activities 2-3 time per week or participation in recreational or local level moderate intensity activity for at least 2 years. * Normotensive (resting systolic blood pressure \<140 mm Hg and diastolic blood pressure \< 90 mm Hg). * Willing to duplicate their previous 24-hr diet, refrain from alcohol and caffeine for 24-hr prior to each visit, refrain from exercise 48-hr prior to each visit. * Refrain from consuming beef liver, chicken liver, eggs, fish, wheat germ and soybeans, butter beans 24-hrs prior to Visit 2 and Visit 3. Exclusion Criteria: * Highly trained or competitive athletes. * Participants who are pregnant or wish to become pregnant during the study or who are lactating and/or currently breastfeeding. * Female participants who are currently breastfeeding. * Female participants who are planning to become pregnant during the study period. * Female participants who test positive on a pregnancy test at screening or prior to first administration of the study product. * Participants with history of drug and/or alcohol abuse at the time of enrolment. (Drinks more than nationally recommended units per week (\>11 units for women; \>17 units for men); alcohol/substance abuse disorder). * Caffeine intake of three or more cups of coffee or equivalent (\>400 mg) per day. * Current smokers or users of any nicotine products in the past 4-weeks. * Has food allergies or other issues with foods that would preclude intake of the Study Products. * Has any significant acute or chronic coexisting health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. * History of malignancy in the previous 5 years except for non-melanoma skin cancer. * Diagnosed, uncontrolled psychiatric disorder. * Hepatorenal, musculoskeletal, autoimmune, or neurologic disease. * Prior gastrointestinal bypass surgery (excluding appendectomy). * Gastrointestinal or metabolic diseases that might impact nutrient absorption or metabolism. * Chronic inflammatory condition or disease. * History of severe or chronic musculoskeletal pain or injury. * History of diabetes, asthma, gout, fibromyalgia or clinical diagnosis of IBS/IBD. * Current or recent use of a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. * Use CNS stimulants or anxiety or ADHD medication. * Use corticosteroids (oral, subcutaneous, intramuscular, or transdermal only). * Use testosterone replacement therapy (ingestion, injection, or transdermal). * Current or recent use of prohibited nutritional or non-nutritional supplements that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results as judged by the investigator. * Use creatine, BCAA, HMB, betaine, beta-alanine, in the past 2 weeks. * Use choline supplements (e.g. choline bitartrate, phosphatidylcholine, citicholine) in the past 4 weeks. * Use omega-3, ginkgo biloba, ginseng, L-theanine, Lion's Mane, ashwagandha in the past 4 weeks. * Individuals who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study. * Participants may be participating in other clinical studies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Atlantia Clinical Trials

    RECRUITING

    Cork, County Cork, P56 W9X2, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.